JP2013533253A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533253A5
JP2013533253A5 JP2013518241A JP2013518241A JP2013533253A5 JP 2013533253 A5 JP2013533253 A5 JP 2013533253A5 JP 2013518241 A JP2013518241 A JP 2013518241A JP 2013518241 A JP2013518241 A JP 2013518241A JP 2013533253 A5 JP2013533253 A5 JP 2013533253A5
Authority
JP
Japan
Prior art keywords
carbon atoms
enantiomer
atoms
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518241A
Other languages
English (en)
Japanese (ja)
Other versions
JP5881692B2 (ja
JP2013533253A (ja
Filing date
Publication date
Priority claimed from US12/827,505 external-priority patent/US9610274B2/en
Application filed filed Critical
Publication of JP2013533253A publication Critical patent/JP2013533253A/ja
Publication of JP2013533253A5 publication Critical patent/JP2013533253A5/ja
Application granted granted Critical
Publication of JP5881692B2 publication Critical patent/JP5881692B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518241A 2010-06-30 2011-06-27 双極性障害を治療する方法 Active JP5881692B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/827,505 US9610274B2 (en) 2010-06-30 2010-06-30 Methods for treating bipolar disorder
US12/827,505 2010-06-30
PCT/KR2011/004676 WO2012002687A2 (en) 2010-06-30 2011-06-27 Methods for treating bipolar disorder

Publications (3)

Publication Number Publication Date
JP2013533253A JP2013533253A (ja) 2013-08-22
JP2013533253A5 true JP2013533253A5 (enExample) 2014-08-07
JP5881692B2 JP5881692B2 (ja) 2016-03-09

Family

ID=45400168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518241A Active JP5881692B2 (ja) 2010-06-30 2011-06-27 双極性障害を治療する方法

Country Status (13)

Country Link
US (2) US9610274B2 (enExample)
EP (1) EP2590645B1 (enExample)
JP (1) JP5881692B2 (enExample)
KR (1) KR101828934B1 (enExample)
CN (1) CN102985085B (enExample)
AU (1) AU2011272156B2 (enExample)
BR (1) BR112012033738A2 (enExample)
CA (1) CA2801241C (enExample)
ES (1) ES2654615T3 (enExample)
MX (2) MX2012014686A (enExample)
PL (1) PL2590645T3 (enExample)
RU (1) RU2653408C2 (enExample)
WO (1) WO2012002687A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133393A1 (en) 2005-06-08 2006-12-14 Sk Holdings Co., Ltd. Treatment of sleep-wake disorders
KR20120098578A (ko) 2009-06-22 2012-09-05 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
BR112015022197B1 (pt) 2013-03-13 2022-06-07 Sk Biopharmaceuticals Co., Ltd. Uso de um composto para o tratamento de cataplexia
CN110638804A (zh) * 2013-07-18 2020-01-03 爵士制药国际Iii有限公司 治疗肥胖
TWI698415B (zh) * 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
CA3036071A1 (en) 2016-09-06 2018-03-15 Jazz Pharmaceuticals International Iii Limited Solvate form of (r)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CN110049966A (zh) 2016-10-06 2019-07-23 杰资制药国际三期有限公司 氨基甲酰基苯丙氨醇化合物及其用途
AU2017374458B2 (en) * 2016-12-14 2023-03-02 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
JP2020528075A (ja) 2017-06-02 2020-09-17 ジャズ ファーマシューティカルズ アイルランド リミテッド 過度の眠気を処置するための方法および組成物
CA3071779A1 (en) 2017-07-31 2019-02-07 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA943862B (en) 1993-06-10 1995-12-04 Lilly Co Eli Method of preventing emesis and treating sexual dysfunction using tetrahydrobenz[cd] indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
PT873308E (pt) 1996-10-10 2002-06-28 Sk Corp Compostos de o-carbamoil-fenilalaninol seus sais farmaceuticamente uteis e processo para a preparacao dos mesmos
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
DE69922186T2 (de) 1998-04-28 2005-05-04 Dainippon Pharmaceutical Co., Ltd. 1-(1-subst.-4-piperidinyl)methyl]-4-piperidin-derivate, verafhren zu deren herstellung, pharmazeutische mixturen und intermediate zu deren herstellung
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
US6589985B2 (en) 2001-02-27 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
HUP0303236A3 (en) 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in the treatment of pain
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
EP1399160A4 (en) 2001-06-12 2004-08-25 Merck & Co Inc NR2B RECEPTOR ANTAGONISTS FOR TREATING OR PREVENTING MIGRAINE
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
MXPA05003065A (es) 2002-09-20 2005-05-27 Pfizer Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4.
EP1620435A1 (en) 2003-04-21 2006-02-01 Pfizer Inc. IMADAZOPYRIDINE COMPOUNDS HAVING 5-HT sb 4 /sb RECEPTOR AGONISTIC ACTIVITY AND 5-HT sb 3 /sb RECEPTOR ANTAGONISTIC ACTIVITY
OA13248A (en) 2003-09-03 2007-01-31 Pfizer Benzimidazolone coumpounds having 5-HT4 receptor agonistic activity.
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
CA2587481A1 (en) 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
CN101189228A (zh) 2005-04-08 2008-05-28 辉瑞产品有限公司 用作i型甘氨酸转运抑制剂的二环[3.1.0]杂芳酰胺
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
WO2006133393A1 (en) 2005-06-08 2006-12-14 Sk Holdings Co., Ltd. Treatment of sleep-wake disorders
CA2612672C (en) 2005-06-22 2014-10-14 Janssen Pharmaceutica, N.V. Treatment for sexual dysfunction
EP1928451B1 (en) 2005-07-26 2011-12-28 SK Biopharmaceuticals Co., LTD Methods for treating substance-related disorders
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
KR20090082213A (ko) 2006-10-13 2009-07-29 얀센 파마슈티카 엔.브이. 페닐알킬아미노 카바메이트 조성물
HUP0700370A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
KR20120098578A (ko) 2009-06-22 2012-09-05 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101097605B1 (ko) 2009-11-04 2011-12-22 알.에프 에이치아이씨 주식회사 도허티 증폭기
ES2743153T3 (es) 2009-11-06 2020-02-18 Sk Biopharmaceuticals Co Ltd Métodos para tratar el síndrome de fibromialgia
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome

Similar Documents

Publication Publication Date Title
JP2013533253A5 (enExample)
JP2013531008A5 (enExample)
RU2012155118A (ru) Способы лечения биполярного расстройства
JP2015505296A5 (enExample)
JP2013510120A5 (enExample)
JP2011504903A5 (enExample)
RU2015143610A (ru) Лечение катаплексии
JP2013536188A5 (enExample)
JP2015516420A5 (enExample)
JP2014051526A5 (enExample)
JP2011517453A5 (enExample)
JP2013538802A5 (enExample)
EA201591353A1 (ru) Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
JP2013509392A5 (enExample)
JP2017533968A5 (enExample)
JP2014511892A5 (enExample)
RU2014149183A (ru) Проницаемые ингибиторы гликозидазы и их применения
JP2010529147A5 (enExample)
JP2012530779A5 (enExample)
JP2011513410A5 (enExample)
RU2010126056A (ru) Органические соединения
RU2013140169A (ru) Противоопухолевое терапевтическое средство
JP2010522710A5 (enExample)
MX2014004144A (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
PH12013501895A1 (en) Ethynyl derivatives as positive allosteric modulators of the mglur5